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Epidemiological evidence and laboratory experimentation over the past 20 
yr supports the conclusion that immunity to group A streptococcal infection is 
type-specific. Antibodies directed against the M proteins, the antigens responsi- 
ble for the specificity of the 50 or more serotypes of group A  streptococci, are 
protective by virtue of their opsonic capacity. This subject has been thoroughly 
reviewed by Lancefield (1). Recent work has demonstrated that several small 
doses, e. g. 10/~g, of highly purified M  proteins induce type-specific bactericidal 
antibodies in rabbits (2). The success of these latter experiments has been the 
impetus for this investigation on the development of a streptococcal vaccine for 
human use. With highly purified M  proteins of types 12,  14, and 24,  we have 
examined the degree of cutaneous hypersensitivity and the level of circulating 
antibodies  in  adults  and  infants.  These  studies  have  furnished  data  on  the 
relative tolerance to M  proteins and the possible extent of previous exposure 
to  these  serotypes.  Secondary bactericidal  antibody responses  have been  in- 
duced in adults injected with M  protein vaccines without provoking untoward 
local or  systemic reactions.  It is  the  purpose of  this  report  to  ex~mlne the 
feasibility of type-specific immunization of humans against group A streptococ- 
cal infections. 
Materials and Methods 
M Protcin.--Hi~hly purified M proteins were prepared from Group A streptococcal cell 
walls as previously described (3). A slight modification of the chromatographic procedure 
eliminated traces of nonspecifie  antigens. To a column of carboxymethyl cellulose equilibrated 
with 0.03 u  sodium acetate and containing the M protein sample was added 0.1 ~ sodium 
acetate buffer at pH 5.5. When the efeuent pH reached 5.5, a linear gradient of 0.1 M  potassium 
phosphate buffer of inc~eAslng pH was applied to the column by adding equal volumes of 
buffers at pH 6.0, 6.5, and 7.0 to a Technicon "Autograd" mixing chamber for the final elution. 
Minor fractions of nonspedfic protein emerged  prior and subsequent to the elution of the main 
peak of M protein near pH 6. 
* Supported by grants from the United States Public Health Service (AM-05996 and AI- 
04342). 
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All buffers used in the chromatographic procedures and for antigen dilutions were prepared 
with pyrogen-free sterile water.  Ringer's lactate buffer (Baxter Laboratories, Inc.,  Morton 
Grove, Illinois) was the final diluent for all parenteral M  protein preparations which were 
sterilized through Millipore falters  before dilution.  Standard procedures for sterility,  pyro- 
genicity, and toxicity testing were followed as prescribed by the United States Public Health 
Service (4); all M  protein preparations met the requirements for these  tests. Alum-precipi- 
tated  M  protein  (APM)  was  prepared  and  standardized  according to  methods  described 
previously (2). 
Serological Procedures.--Type-speci~c  precipitin  reactions were  carried  out  in  capillary 
tubes according to Swift et al. (5), with specific rabbit antisem obtained from the United States 
Communicable Disease  Center,  Atlanta,  Georgia. Antisem for hemagglutination standards 
were from rabbits immunized with purified M  proteins in incomplete Freund's adjuvant (2). 
The hemagglutination (HA) assay of type-specific antisera was  performed  according to  our 
standard technique (6).  Sera from adults were obtained from clotted blood obtained by veni- 
puncture. Peripheral blood of infants was  obtained  by  heel  puncture. The  initial  dilution 
for all HA assays was 1:100; sera not reacting at  this concentration were  considered nega- 
tive. The geometric mean HA titers were calculated as antilog (1  ~'.. log A~) where A, equal 
the reciprocals of the highest positive dilutions of n samples. 
The indirect bactericidal test was  performed  essentially as  described  by Lancefield  (7) 
with slight modification (2). A bactericidal index (8) scale from zero (no inhibition) to 4 (com- 
plete phagocytosis) has been devised. This scale is based on the ratio R  of the total colony 
count of the inoculum at dilutions of 1:16,  1:64, and  1:256 to the total number of colonies 
at these dilutions in the presence of antibody. The 5 values for R  chosen on the basis of ac- 
cumulated data, are grouped as  10 or greater, 9  to 5, 4  to 2,  1, and less than 1, and these 
groups correspond to index values of 4, 3, 2, 1, and 0, respectively. R is significant only when 
the total colonies obtained after 3 hr in the presence of normal rabbit serum minus the original 
inoculum is  greater  than  1500.  For  example,  a  serum  allowing  a  total  surviving colony 
count of 43, when the initial inoculum was 215 would have a value for R of 215/43 or 5, and 
thus a  bactericidal  index  of  3.  This method  of  computation of  the  bactericidal  index is 
simple and permits an index for sera that completely eliminate all streptococci in the phago- 
cytic system. 
Clinical  Procedures.--Cutaneous  hypersensitivity  was  determined  by  injecting  intra- 
cutaneously on the volar surface of the forearm 0.1 ml of sterile M  protein in Ringer's lactate 
buffer. Subcutaneous injections of soluble M  protein or AMP in 0.5 ml of Ringer's lactate 
buffer were administered in the deltoid region. Subjects with histories or symptoms of heart 
or kidney disease or chronic streptococcal infections were excluded from the study. 
Gel Ele~trophoresis.--Acrylamide gel disc electrophoresis was  performed  with a  Model  6 
Canalco apparatus by methods described (3). For the isolation of the multiple fractions com- 
prising the M  protein, a  preparative gel electrophoresis column 1.8 X  8 cm was constructed 
similar to that described by Lewis and Clark (9). 10 mg samples of M  protein were separated 
into constituent fractions under a potential of 400 v at 33 ma for 90 rain at room temperature. 
Small-bore longitudinal cores were cut from the large columns of gel and  stained.  Slices  cor- 
responding to areas of stained protein were cut from the main colunms of gel, and protein was 
recovered from the slices by electrophoresis in dialysis sacks. The eluted protein was concen- 
trated by lyophili~ation, dialyzed against Ringer's lactate buffer at  5°C,  and sterilized by 
filtration through Millipore membranes.  For  immunodiffusion reactions it  was  discovered 
that columns of gel with stained bands of M  protein could be soaked in buffered saline for 
several hours to remove the acetic add and the stained M  protein bands were serologically 
active when sections were embedded in agar. EUGENE  N.  ~FOX, M.  K.  WITTNER,  AND  ALBERT DORFMAN  1137 
RESULTS 
Cutaneous Hypersensitivity  and Circulating Antibodies  to M  Protvins.--Adult 
volunteers between 21 and 35 yr of age, selected from a population of medical 
students and laboratory personnel, were skin-tested with  1 #g intracutaneous 
doses of purified M  proteins. Concurrently, serum antibody titers were assayed 
by passive hemagglutination (HA). Table I  summarizes the data accumulated 
in 106  tests in 91 persons of whom 15 were tested  with  both M  protein sero- 
types. In the two groups of subjects, 70 and 84% exhibited a delayed cutaneous 
hypersensitivity (DCH) to M  serotypes 12 and 24, respectively, and over 90% 
TABLE  I 
Hemagglutination Tilers and Delayed Hypersensitivity to Types 12 and 24 M Proteins in Adults 
Distribution  Type 12  Type 24 
Number of subjects tested* 
Positive delayed cutaneous hypersensitivity (DCH) 
Hemagglutination (HA) titer >  100 
Geometric mean titer 
Positive DCH and positive HA 
Positive DCH and negative HA 
Negative DCH and positive HA 
Negative DCH and negative HA 
68 
48 
(70%) 
64 
(94%) 
184o 
46 
(68%) 
3 
(4%) 
18 
(26%) 
1 
38 
32 
(847o) 
315 
(97%) 
760 
27 
(84%) 
o 
4 
(12%) 
1 
* 15 subjects were tested for both serotypes. 
5 Sera of 6 subjects were unavailable for HA titration. 
of both groups had circulating antibodies with titers of 100 or greater. DCH was 
considered positive when areas of erythema were greater than 0.5 cm in diam- 
eter at the height of the reaction.  Extremely reactive subjects  had erythema- 
tous reactions up to 6 cm accompanied by swelling and induration.  HA titers 
in a few individuals increased two- to fourfold 1 wk after the skin testing; the 
values used to calculate the geometric mean titers were those obtained from 
sera taken immediately prior to the intracutaneous  injection.  The geometric 
mean titer following the skin tests increased slightly, but was not considered 
significant in this group. It is noteworthy that there was no correlation between 
an increase in titers and degree of DCH, nor was there a  correspondence of 
either reaction with age, sex, or race. The absence of DCH was not correlated 
with a lack of circulating antibodies. In summary, a large majority of the normal 
young adults tested had circulating antibodies and exhibited a  DCH to types 
12  and  24  M  proteins. 1138  ANTIGENICITY OF THE M  PROTEINS. HI 
In contrast to adults, a significantly lower order or reactivity was observed in 
a  group of 59 infants between the ages of 6 months and 3 yr (Table II). These 
children  were tested with types 14 and 24 M  proteins in the same manner as 
the adult group. It may be seen that 8% of the skin tests and 13% of the HA 
assays  (of sera taken subsequent  to skin testing)  were positive.  42 of the 59 
infants had neither  circulating antibodies  nor exhibited  a  DCH  to either  M 
protein; this may be compared to 2 %  of the adults who were negative in both 
TABLE II 
ttemagglutination Titers and Delayed kyperse~ili~ty tO Types 14 and 24 M Proteins in Infants 
Distribution among 59 subjects,  ages 6 months to 3 yr*  Type t4  Type 24 
4  5  Positive delayed cutaneous hypersensitivity~  (DCH) 
Hemagglutination  (HA) titers greater than 100 before skin 
test 
HA titers greater than 100 7 days after skin test§ 
Y 
s% 
1  2 
3  11 
Positive DCH and positive HA 
Positive DCH and negative HA 
Negative DCH and positive HA 
Negative DCH and negative HA 
13% 
XtL  3 
2  1 
2  8 
42  43 
77% 
* 59 infants tested with 2 serotypes; 8 sera were unavailable for type 14 HA tests 7 days 
after inoculation. 
2 subjects exhibited DCH to both serotypes. 
§ Geometric mean  titer of 1000 for both serotypes  calculated  together. 
I1 This subject exhibited DCH and positive HA titers for both serotypes. 
respects.  In the  infants  as in  the  adults  there  appeared  to be no correlation 
between skin reactivity and circulating type-specific antibody, nor was there a 
correlation of these parameters with sex or race. 25 of the infants in this group 
were under 1 yr of age; none had circulating antibodies or DCH to the M  pro- 
teins.  The increase in HA titers  of 8  subjects  subsequent  to skin-testing  may 
indicate that a  1 ~zg dose of M  protein induces some degree of active immuniza- 
tion. 
Nature  of the  Delayed  Cutaneous  Response.--All  putatively  hypersensitive 
persons reacted to intxacutaneous injections of purified M  proteins in the same 
general manner. Erythema appeared in about 6 hr, reached a maximum between 
18 and 24 hr, and virtually disappeared within 72 hr; the more intense reactions EUGENE  N.  FOX,  M.  K.  WITTNER,  AND  ALBERT  DORFMAN  1139 
were accompanied by swelling and induration. The lack of reactivity in approx- 
imately 20% of the adults  and  90 %  of the infants and  the differences in the 
reactions to several serotypes among individuals indicated  that the cutaneous 
reactions were in all likelihood a  manifestation of delayed hypersensitivity to 
M  proteins and not a  result of nonspecific toxicity to undetected streptococcal 
antigens. 
In order to demonstrate further that type 12 M protein per se was responsible 
FIG. 1. Acrylamide  gel electrophoretic  patterns of type 12 M protein, showing the multiple 
molecular structure  (left) and  5 fractions obtained from a preparative  electrophoretic gel 
column. 
for the DCH, the M protein was fractionated by acrylamide gel electrophoresis 
into its multiple components (3). We had previously shown by gel electrophore- 
sis that purified M  proteins extracted from cell walls by hot acid are obtained 
as multiple  molecular fractions,  all  of which  are  serotogically identical  when 
separated and recovered from the acrylamide gel. Fig. 1 (left) is the acrylamide 
gel disc electrophoretic pattern of purified type 12 M protein. From preparative 
columns (see Materials and Methods), five fractions of M  protein were isolated 
as illustrated. These components of type 12 M protein were administered intra- 
cutaneously  to  3  individuals  of  predetermined  reactivity.  Fig.  2  shows  the 
cutaneous reactions of 1 subject at 24 hr to a  1 /zg dose of each fraction. Each 1140  ANTIGENICITY  OF  THE  M  PROTEINS.  III 
injection  produced  a  cutaneous  reaction  of  approximately  equal  intensity. 
Similar  results  were observed in the other 2 subjects. 
Complete  digestion  of M  proteins  by  trypsin  abolished  the  DCH  reaction 
in  persons  of known  sensitivity.  It  was  of interest  to  determine  whether  at- 
FIG. 2. Delayed cutaneous reactions at 24 hr from Iug doses of the five separate fractions of 
type 12 M protein, as shown in Fig. 1. Injection site 6 is a control preparation  from a section 
of gel containing no M protein. 
tenuated  (partially degraded)  M  proteins would induce less cutaneous reaction 
while  maintaining  antigenic  specificity.  Limited  tryptic  digestion  was carried 
out in the following manner.  To 1 mg samples of type 12 M  protein in  1.0 ml 
of  buffered  saline  at  pH  7.0  at  37°C  was  added  5  /sg of  crystalline  trypsin 
(Worthington  Corporation,  Freehold,  New  Jersey)  in  0.2  ml  of  buffer.  The 
mixtures  were  incubated  at  37°C  and  after  appropriate  intervals  (Table  III) 
10  /~g  of  crystalline  soy bean  trypsin  inhibitor  (Worthington)  in  0.05  ml  of 
buffer ~as  added.  The temperature  was maintained  at 37°C for an additional 
l0 min and then the mixture was chilled to 0°C. Table III shows the changes in 
antigenic activities with increased tryptic digestion. Loss of some precipitating EUGENE  N.  FOX,  M.  I(.  WITTNER,  AND  ALBERT  DORFMAN  1141 
activity was observed after 5 rain, but the residual antigen still had the capacity 
to partially inhibit  the  HA reaction.  In Fig.  3  are the  acrylamide gel electro- 
phoretic  patterns  of the  M  protein  fractions  during  the  course  of tryptic  de- 
gradation. Within 5 min, the M  protein fractions were converted to polypeptides 
of entirely new mobilities, yet they maintained  a  considerable portion of type- 
specific antigenic activity. When slices from the stained areas of the acrylamide 
gel containing the 5 min digest of M  protein were placed in wells of agar plates 
TABLE III 
Effect  of  Trypsin  on  the Antigenlcity  of  Type  12  M  protein 
Sample  Time of trypsinization  Precipitin  Hemagglutination  DCH to 1 ~tg; diameter 
reaction*  inhibition  test  of erythema (Fig. 5) 
rain 
0 
(no trypsin) 
1 
5 
15 
30 
90 
90 
(no M protein) 
++++ 
++++ 
+++ 
++ 
reciprocal of dilulion~ 
0 
0 
12,800 
25,600 
-4-  51,200 
102,400 
102,400 
c~a 
6§ 
4§ 
1.5 
1.0 
(omitted) 
0.6 
0 
* Precipitin  reaction  recorded as estimated degree of precipitation in a capillary tube with 
undiluted  type 12 serum. 
:~ Samples diluted  to contain  the equivalent  of 80 #g of original M protein per milliliter; 
0.5 1111 were mixed with 0.5 ml of a  1:25 dilution of type 12 antiserum at 37°C for 30 min 
before titration. 
§ Erythema accompanied  by swelling and  induration. 
for immunodiffusion  reactions,  precipitin  lines  of identity  were observed with 
type-specific antisera  (Fig.  4). 
3  adult  volunteers  of known  hypersensitivity  reacted  approximately  to  the 
same degree when challenged intracutaneously  with the trypsinized M  protein 
samples; one result  is shown in  Fig.  5.  Each dose contained  the  equivalent  of 
1 ~g of M  protein (determined before tryptic digestion). The M  protein samples 
treated  with  trypsin for 5  min or longer initiated  only minimal DCH.  It may 
be assumed that the remaining low degree of DCH induced  by the M  proteins 
hydrolyzed  with  trypsin was due  to residual polypeptides that may be seen in 
Fig.  3  (30 and  90 rain hydrolysates). 
These data demonstrate  that type 12 M  protein,  capable of evoking a  cuta- 
neous  response  in  hypersensitive  persons,  may  be  partially  degraded  with 
trypsin to virtually eliminate the cutaneous reaction and still maintain a portion 
of type-specific antigenic  reactivity.  The implications  of these  results in term; 
of a  vaccine preparation will be discussed. 1142  ANTIGENICIT¥  OF  THE  M  PROTEINS.  III 
Responses of Adults to Soluble and Alum-Precipitated M  Protein Vaccines.-- 
11 adults showing no skin sensitivity to 1 tzg doses of type 24 M  protein were 
given subcutaneous injections of 20 ~g of the antigen. There were no untoward 
local  or systemic reactions  resulting from these  injections.  The antibody re- 
sponses measured by HA prior to and 10 days following the injection are shown 
FIG. 3. Acrylamide gel electrophoretic patterns of type 12 M  protein samples treated with 
trypsin  for  various intervals of  time  (see  text).  Tube  C  contains only  the  trypsin-trypsin 
inhibitor complex (sample 7 of Table III). 
in  Table  IV.  (The  maximum  response  appeared  between  10  and  14  days.) 
All  11  subjects responded, with  an  average  threefold increment in the type- 
specific HA titer. 
Our previous experiments with rabbits  (2)  demonstrated that two or three 
10 #g doses of M  proteins administered with adjuvants in repository injections 
stimulated  high-titer  protective antibodies.  As  a  result  of these  experiences, 
type 12 alum-precipitated M  protein (APM), composed of 10 #g of M  protein 
adsorbed onto 2 mg of aluminum hydroxide in 0.5 ml of Ringer's lactate buffer, EUGENE N.  FOX; M.  K.  WITTNER~ AND ALBERT DORFMAN  1143 
was  administered subcutaneously to  a  panel of  adult  volunteers previously 
screened for cutaneous nonreactivity to the type 12 M  protein. Serum samples 
were  obtained just prior  to  and at  four weekly intervals after  the  injection. 
The maximum increase in titer appeared between 1 and 2 wk. Table V  sum- 
marizes the results with 22  adults injected with the APM vaccine. 20 of the 
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FIGs. 4 a and 4 b. Diagram of stained gel electrophoretic preparation of 5 min trypsin digest 
of type 12 M protein. 2-ram sections from the numbered areas were placed in wells of an agar 
plate and reacted by immunodiffusion  with type-specific  serum (ab) placed in the inner wells. 1144  ANTIGENICITY  OF  THE  M  PROTEINS.  III 
subjects responded with antibody titer increments averaging fivefold over the 
preinjection level. 
In a  group of 19 persons who received a  1 #g dose of soluble M  protein intra- 
cutaneously, but no vaccine, only 3 showed an increase in the HA titer and the 
over-all mean  in  this  latter group  did not  increase  significantly in  the  2  wk 
interval following the skin test. A comparison of those who were skin-tested and 
received vaccine  and  those  who  received  only  the  skin  test  is  shown  in  the 
histogram of  Fig. 6,  in  which  the  antibody titer increment  of each  subject is 
FIG. 5. Delayed cutaneous  reactions (24 hr) to 1 ~g samples of type 12  M  protein treated 
with trypsin as indicated in Table III. The area distal to the 90 min reaction was the site of 
injection of sample 7, the trypsin-trypsln inhibitor blank (C of Fig. 3). 
plotted. The data of these two groups are compared to illustrate that the skin- 
test dosage given to those subjects who received APM vaccine 24 hr later had 
no significant effect on the antibody responses. In the group of 19 persons who 
were skin-tested only, 14 exhibited DCH, but there was no correlation between 
the degree of DCH and the HA titers before or after the injections. However, 
because  the subjects who exhibited DCH  were omitted from  the vaccine trial, 
there were no data to determine whether the hypersensitive state could influence 
the antibody response in  these persons. 
Sera from a  number  of subjects were selected for bactericidal assays (Table 
V).  In general, sera with HA titers of 3200  or greater were bactericidal. Sera 
from those subjects whose HA titers increased from below this to titers above 
3200  had  type-specific bactericidal antibodies presumably resulting  from  the EUGENE  N.  FOX,  M.  K.  WITTNER,  AND  ALBERT  DORFMAN  1145 
APM vaccine. It was observed that postinjection sera with titers above 100,000 
and occasionally 50,000 had  type-specific precipitin  activity when assayed by 
the  capillary technique,  whereas  sera of lower titers  from these subjects prior 
to immunization gave no visible reaction with soluble M  proteins. 
Relationship  of M  Proteins  and  Human  Tissue.--Indirect  support  for  the 
current  hypothesis  of  the  autoimmune  pathogenesis  of rheumatic  fever  and 
streptococcal glomerulonephritis stems from the demonstration of Kaplan and 
Meyeserian that a  streptococcal cell wall antigen cross-reacts immunologically 
with  human  heart  tissue  (10).  Subsequent  serological  studies  with  heart  and 
TABLE IV 
Response to 20 #g of Type 24 M  Protein in Ad*dts 
Subject 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Hemagglutination titer (reciprocal of dilution) 
Preinjection 
200 
1600 
800 
200 
400 
1600 
1600 
800 
800 
1600 
40O 
10 day postinjection 
800 
3200 
3200 
400 
3200 
3200 
3200 
3200 
3200 
3200 
1600 
Geometric mean  700  2200 
kidney  tissues  have  corroborated  this  initial  discovery although  the  various 
investigations  do not necessarily agree on the composition or cellular origin of 
the streptococcal antigens  (11-13).  If induced autoimmune reactions prove to 
be  etiologic  factors in  the  sequellae  of streptococcal  infections,  a  vaccine  for 
human use must be free of these cross-reacting antigens; this was assessed in the 
following ways. 
17 of the highest titer antisera from our previous study of rabbits immunized 
with types  12 and  14 APM or M  proteins in oil emulsions  (2)  were tested for 
immunological cross-reactivity with human heart tissue by fluorescent antibody 
techniques. 1 None of these sera showed a  significant affinity for human heart 
tissue.  However,  it  ~as  reported  to  us  by Dr.  Melvin  Kaplan  that  1  serum 
1  These tests were performed in the laboratories of Doctors Melvin Kaplan, Earl Freimer, 
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TABLE V 
Antibody  Res wnses to  Alum-Precipitated  Type 12  M  Protein  Vaccine in  Adults 
Hemagglutination titer X  10  -2  Bactericidal index* 
(reciprocal  of dilution) 
Subject 
Preinjection  14 days postinjection  Preinjection 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
Mean~ 
32  128 
64  64 
64  256 
128  2048 
64  512 
32  128 
0  32 
32  64 
64  64 
256 
512 
256 
16  32 
2  8 
16  128 
64  256 
32  1024 
16  32 
16  32 
8  128 
32  512 
32  128 
27  135 
128 
16 
16 
14 days postinjection 
0  4 
0  4 
2  4 
0  0 
4  4 
0  4 
4  4 
0  2 
1.25  3.25 
* See materials and Methods for calculation of bactericidal index. 
Geometric mean of HA titers and arithmetic mean of bactericidal indices. 
furnished  by our laboratory  cross-reacted  with human  heart  tissue.  This anti- 
serum  was  from  a  group  of rabbits  made  hyperimmune  with  repeated  large 
doses (2 rag) of type 12 M  protein in mineral oil emulsion. 
Rabbit antiserum against the membrane fraction of a  type 25 group A  strep- 
tococcus,  exhibiting  a  strong  immune  reaction  with  human  heart  tissue  (12) 
was  supplied  to  us  by Dr.  Earl  Freimer.  This  antiserum  failed  to  agglutinate 
erythrocytes passively sensitized with types 12, 14, or 24 M  proteins. In addition EUGENE  N. ~FOX,  M. K. WlTTNER, AND ALBERT DOR~MAN  1147 
purified type 12 M  protein failed to react in ~mmunodiffusion tests with rabbit 
antisera prepared against pooled human glomernlar membranes  ~ although the 
latter  sera produced  strong  precipitin  reactions  with  the  solubilized  kidney 
antigens (13). 
q/J 
I-, 
Im,I 
in 
z) 
u) 
12, 
11, 
9, 
8. 
7. 
6. 
4 
3 
2 
1, 
10/zg  A  PM-12  CONTROL 
0  2  4  8  16  32  64  0  2  4  8  16  32 
HEMAGGLUTINATION  INCREMENT 
FIG. 6. Histogram of distribution of HA titer increments in 22 subjects following a sub- 
cutaneous 10/ag dose of type 12 APM (left) and a control group (right) of 19 subjects who 
received a 1/~g intracutaneous injection of soluble type 12 M protein (see Table V). 
DISCUSSION 
The delayed cutaneous reactions  we have observed with purified  IV[  proteins 
resemble the  so called  "Jone-Mote" hypersensitivity.  The latter  is  a term coined 
by Raffel and Newel (14) to describe  a transient  hypersensitivity (to strepto- 
coccal  and other antigens)  possibly  first  characterized  by Jones and Mote (15). 
Lawrence (16)  described a  similar type of evanescent cutaneous sensitivity in 
90%  of the  adult  patients  in  his  study  of  passive  transfer  reactions  using 
partially purified M  proteins. Our data show that only 8% of the infants tested 
2 This test was carried out by Dr. A. S. Markowitz. 1148  ANTIGEIqICITY OF THE ~  PI~OTEINS. HI 
exhibited the DCH.  It can be inferred that acquired DCH in adults results 
from life-long exposure, clinically or subclinically, to many serotypes of group 
A streptococci. These conclusions are also supported by the detection of HA 
antibodies to M  proteins in most of the adults and only a few of the infants, 
although the lack of reactivity in infants could also be attributed to diminished 
immunological responsiveness. Previous studies in humans with streptococcal 
culture filtrates, cellular extracts, or partially purified M proteins also showed a 
much higher incidence of cutaneous reactions in adults than in infants and 
children (17-19). However, owing to the relative severity of many of the local 
and systemic reactions encountered by these and other workers (20,  21),  the 
present  investigation was  conducted cautiously and conservatively. On  the 
basis of our knowledge of the antigenic purity of the M  proteins used in this 
study, we conclude that in the present work, the tissue and humoral responses 
observed are type-specific indicators of streptococcal exposure. 
We have not yet determined whether purified M proteins per se can induce a 
state of hypersensitivity in humans. Rabbits that received up to six injections 
of 100 #g of M  protein over a period of 3 months still exhibited no DCH (6). 
Lawrence's study (22) in humans of the passive transfer of DCH showed no 
"conversions" in  nonreactive  subjects  who  received  a  number  of  doses  of 
partially purified M proteins. In the data presented here, there appears to be no 
correspondence between the elicitation of a DCH response and HA titers either 
before or following a challenge of M protein. In future studies in larger popula- 
tions, it may be revealed that M-specific DCH may be a  prognostication of 
relative type-specific immunity to group A streptococcal infection. 
The hemagglutination test  using highly purified M  proteins  adsorbed  to 
erythrocytes is an extremely sensitive and specific  antibody assay. Our  HA 
data on the antibody responses of adults to APM vaccine and the general cor- 
respondence with increases in the bactericidal activity of postinjection sera 
indicate  that  the  HA assay  may be  a  useful technique for  measuring the 
efficacy of M protein vaccines in humans; similar conclusions have been borne 
out in our results with rabbits (2, 6). 
M  proteins  partially degraded  by trypsin retain  substantial antigenicity 
when assayed in vitro and evoke only minimal delayed cutaneous reactions in 
hypersensitive persons. Acrylamide gel electrophoresis demonstrates that the 
large polypeptides resulting from partial hydrolysis and  not  residual  unde- 
graded proteins are the antigenic components. We have immunized a group of 
6 rabbits with APM prepared from type 12 M  protein exposed to trypsin for 
5 rn[n.  HA titers after a  series of three injections were comparable to those 
obtained with undegraded APM vaccines (2).  Trypsin-attenuated M  proteins 
may obviate a problem in the use of polyvalent APM vaccines in individuals 
possessing DCH to one or more serotypes. 
Due  to  the  fact  that  type-specific antibodies  were  present  prior  to  the EUGENE  N.  FOX,  M.  K.  WITTNER,  AND  ALBERT  DORFMAN  1149 
antigenic stimulus, an increase in antibody titers in the majority of subjects who 
received soluble M proteins  or APM vaccine was most likely a secondary re- 
sponse.  Potter  et al.  (20) reported  similar  an~mnestic  reactions  in persons 
injected with streptococcal  cell walls. In this latter work, subjects  were chal- 
lenged with streptococcal  walls of homologous strains  isolated  from specific 
upper respiratory infections. 
An essential feature of the M protein preparations administered in the present 
study is the lack of toxicity in experimental animals and humans. Our prepara- 
tions of soluble and APM vaccine administered to mice and guinea pigs in doses 
ten times greater than those introduced into humans, or several thousand times 
greater,  calculated on a  body weight basis,  were nontoxic and nonpyrogenic. 
Schwab  (23) has demonstrated that group A streptococcal  cell walls contain 
a cytotoxic necrotizing factor, presumed to be the mucopeptide-C  polysaccha- 
ride complex. It is obvious that vaccines composed of streptococcal cell walls or 
impure M  proteins may have serious deleterious  effects resulting from this 
necrotizing factor. 
Large doses of APM vaccine  administered intraperitonealy in guinea  pigs 
produced an encapsulated granuloma which was not observed with soluble M 
proteins. This localized lesion in the peritoneal membrane at the site of inocula- 
tion was  histologically  identical to  that observed  by Holt  (24) with alum- 
precipitated diphtheria toxoid. In the latter work as with APM vaccine, these 
nodules caused by the deposition of aluminum hydroxide were nearly resorbed 
within a month after the injection. 
If the cross-reaction  of human tissues and streptococcal  antigens proves to 
be an etiologic factor in the postinfectious  events leading to rheumatic fever 
and glomerulonephritis  through auto~mmune mechanisms,  the present study 
most likely excludes the M  proteins  from culpability. The significance of the 
single  instance of antigenic  cross-reactivity  of hyper]mmune anti-M  rabbit 
serum and human heart tissue is difficult to evaluate. However, in view of the 
absence of cross-reacting antibodies  in all other rabbit sera, further testing of 
M protein vaccines in humans is reasonably safe. Thus, our data demonstrate 
that small doses of highly purified M  proteins are capable  of inducing type- 
specific anamnestic antibodies in humans under reasonably safe circumstances. 
Studies  are now possible on larger populations to determine if ~mmunization 
with multiple serotypes  of M  proteins  will afford protection against group A 
streptococcal infections. 
SUMMARY 
Highly purified M proteins were used for determining cutaneous hypersen- 
sitivity and type-specific circulating  antibodies  in normal adults and infants. 
80% of 91 adults and 8% of 59 infants exhibited a transient delayed cutaneous 
reaction to at least two of types 12, 14, and 24 M proteins. Antibodies assayed 1150  ANTIGENICITY 0]~  ~£B..v5 M  PROTEINS.  rrr 
by passive hemagglutination were observed in 90% of the adults and 13% of 
the infants. 
Vaccines of 10  /~g of alum-precipitated M  protein or 20  #g of the  soluble 
antigen  were administered  to adults  not  exhibiting delayed hypersensitivity. 
Within 2 wk hemagglutination titers increased significantly in 31 of 33 subjects. 
Prelmmunization antibody levels indicated that these responses were probably 
anamnestic reactions from previous exposures to homologous serotypes of group 
A  streptococci.  Sera  exhibiting large increments  in  antibody  titers  resulting 
from  M  protein  inoculations  also  had  type-specific  bactericidal  properties. 
"Attenuated"  M  proteins,  produced  by partial  degradation  with  trypsin in- 
duced only minimal cutaneous reactions in hypersensitive adults, but still re- 
tained most of the antigenic specificity when assayed in vitro and in vivo. 
The utility of M  protein vaccines for human use is discussed in reference to 
the  low  incidence  of cutaneous  hypersensitivity in  infants,  the potentials  of 
polyvalent attenuated M protein vaccines and the apparent absence of immune 
cross-reactivity between pure M  proteins and human heart and kidney tissues. 
The authors express their appreciation to Dr. Melvin Kaplan, Western Reserve University, 
Doctors Earl Freimer and John Zabriskie of The Rockefeller University and Dr. A. S. Marko- 
witz of the Hektoen Institute for their cooperation in this study. We also thank Mrs. Tamara 
Smoot and Dr. Priscilla Kao for their expert technical assistance. 
We are grateful to Doctors Jacob Holper and Donald Stoppel of Abbott Laboratories, Inc., 
for their cooperation in the safety testing of the M protein vaccines, and to Dr. Howard M. 
Jacobs for h/s aid in part of the clinical testing. 
BIBLIOGRAPHY 
1.  Lancefield,  R.  C.,  Current knowledge  of type-specific  M  antigens  of group A 
streptococci, J. Immurwl.,  1962, 89, 307. 
2.  Fox,  E.  N.,  and Wittner,  M.  K.,  Antigenicity of the  M  proteins  of group A 
hemolotyic streptococci.  II. Antibody response in rabbits to vaccines prepared 
with oil emulsions and aluminum hydroxide, J. Immunol., 1966, 9'/, 86. 
3.  Fox,  E.  N.,  and Wittner,  M.  K., The multiple molecular structure  of the  M 
proteins of group A streptococci,  Proc. Nat. Acad. Sc.,  1965, fi4, 1118. 
4.  Public Health  Service  Regulations  for Biological  Products,  Title 42,  Part  73, 
1965, United  States  Public  Health  Service  Regulations  No.  73-74,  General 
Safety, p. 14. 
5.  Swift,  H. F., Wilson,  A. T., and Lancefield,  R.  C.,  Typing group A  hemolytic 
streptococci by M  precipitin  reactions  in  capillary pipettes,  J.  Exp.  Med., 
1943, 78, 127. 
6.  Fox, E. N., Anfigenicity of the M  proteins of group A  hemolytic streptococci, 
J. Immurwl.,  1964, 93, 826. 
7.  Lancefield,  R.  C.,  Differentiation  of group A  streptococci with  a  common R 
antigen into three serological  types, with special  reference  to the bactericidal 
test, J. Exp. Med.,  1957, 106, 525. 
8.  Stollerman,  G. H., Kantor, F. S., and Gordon, B. D., Accessory plasma factors EUGENE  N. FOX, ~[. K. V~ITTIqER, AND  ALBERT DOI~FMAN  1151 
involved in the bactericidal  test for type-specific antibody to group A strep- 
tococci. I. Atypical behavior of some human and rabbit blood, J. Exp. Med., 
1958, 108, 475. 
9. Lewis, U.  J., and Clark,  M.  O.,  Preparative methods for  disc electrophoresis 
with special reference to the isolation of pituitary hormones, Anal. Biochem., 
1963, 6, 303. 
10. Kaplan, M. H., and Meyeserian, M., An immunological cross-reaction between 
group A streptococcal cells and human heart tissue, Lancet, 1962, 1, 706. 
11. Kaplan, M. H., and Suchy, M. L., Immunological relation of streptococcal and 
tissue antigens. II. Cross-reaction of antisera  to mammalian heart tissue with 
a cell wall constituent of certain strains of group A streptococci, J. Exp. Med., 
1964, 119, 643. 
12. Zabriskie, J. B., Freimer, E. H., and Seegal, B., An immunological relationship 
between streptococcal membranes  and human heart tissue, Fed. Proc., 1964, 
23, 343. 
13. Markowitz, A. S., and Lange, C. F., Jr., Streptococcal related glomerulonephritis. 
I.  Isolation,  immunochemistry  and  comparative  chemistry of  soluble  frac- 
tions  from  type 12 nephritogenic  streptococci and human glomeruli, J. Im- 
munol., 1964, 92, 565. 
14. Raffel, S., and Newel, J. M., The "delayed hypersensitivity"  induced by antigen- 
antibody complexes, J. Exp. Med., 1958, 108, 823. 
15.  Jones,  T.  C., and Mote, J. R., The phases of foreign protein  sensitization  in 
human beings, New England J. Med., 1934, 210, 120. 
16. Lawrence, H. S., Transfer of skin reactivity to streptococcal products, in Strep- 
tococcal Infections,  (M. McCarty, editor),  New York,  Columbia  University 
Press, 1954, 152. 
17. Mackenzie,  G. M., and Hangar, F. M., Jr., Allergic reactions  to streptococcus 
antigens, J. lr~r~uncl., 1927, 13, 41. 
18. Howell,  K.  M.,  and  Corrigan,  M.,  Skin  reactions  with bacterial  filtrates of 
anhemolyfic streptococcus, hemolytic streptococcus and B. typhosus, J. Infect. 
D/s., 1928, 42, 149. 
19. Schmidt, W. C., Type-specific antibody formation in man following injection of 
streptococcal M protein, J. Infect. Dis., 1960, 106, 250. 
20. Potter, E. V., Stollerman, G. H., and Siegel, A. C., Recall of type-specific anti- 
bodies in man by injections of streptococcal cell walls, J. Clin. Inv., 1962, 41, 
301. 
21. Wolfe, C. K., Jr., Hayashi, J. A., Walsh, G., and Barkulis, S. S., Type-specific 
antibody response in man to injections of cell walls and M protein from Group 
A, type 14 streptococci, J. Lab. and Clin. Med., 1963, 6l, 459. 
22. Lawrence, H. S., The cellular transfer in humans of delayed cutaneous reactivity 
to hemolytic streptococci, J. Immunol.,  1952, 08,  159. 
23.  Schwab, J. H., Biological properties  of streptococcal cell-wall particles.  I. De- 
terminants of the chronic nodular lesion of  connective  tissue,  J.  Bacteriol., 
1965, 90, 1405. 
24. Holt, L. B., Developments  in Diphtheria Prophylaxis,  London, William Heine- 
mann, Ltd., 1950, 90. 